Evidence map›Paper›PMID 41289576›Full record

Trial reportJournal of medical Internet research2025

AI-Assisted Cardiovascular Risk Assessment by General Practitioners in Resource-Constrained Indonesian Settings Using a Conceptual Prototype: Randomized Controlled Study.

Anindya Pradipta Susanto, David Lyell, Bambang Widyantoro, Dafsah Arifa Juzar, Anwar Santoso, Shlomo Berkovsky, Farah Magrabi

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anindya Pradipta SusantoCentre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, 75 Talavera Road, Sydney, 2113, Australia, 61 423309268.ORCID http://orcid.org/0000-0001-5155-6904
David LyellCentre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, 75 Talavera Road, Sydney, 2113, Australia, 61 423309268.ORCID http://orcid.org/0000-0002-2695-0368
Bambang WidyantoroDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Centre Harapan Kita Hospital Jakarta, Universitas Indonesia, Depok, Indonesia.ORCID http://orcid.org/0000-0001-5325-4125
Dafsah Arifa JuzarDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Centre Harapan Kita Hospital Jakarta, Universitas Indonesia, Depok, Indonesia.ORCID http://orcid.org/0000-0001-8392-4759
Anwar SantosoDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Centre Harapan Kita Hospital Jakarta, Universitas Indonesia, Depok, Indonesia.ORCID http://orcid.org/0000-0001-8247-4151
Shlomo BerkovskyCentre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, 75 Talavera Road, Sydney, 2113, Australia, 61 423309268.ORCID http://orcid.org/0000-0003-2638-4121
Farah MagrabiCentre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, 75 Talavera Road, Sydney, 2113, Australia, 61 423309268.ORCID http://orcid.org/0000-0002-8426-5588

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preventive strategies integrated with digital health and artificial intelligence (AI) have significant potential to mitigate the global burden of atherosclerotic cardiovascular disease (ASCVD). AI-enabled clinical decision support (CDS) systems increasingly provide patient-specific insights beyond traditional risk factors. Despite these advances, their capacity to enhance clinical decision-making in resource-constrained settings remains largely unexplored. Objective: We conducted a randomized controlled study to assess the effect of AI-based CDS on 10-year ASCVD risk assessment and management in primary prevention. Methods: In a 3-way, within-subject randomized design, doctors completed 9 clinical vignettes representative of primary care presentations in a resource-constrained outpatient setting. For each vignette, participants assessed 10-year ASCVD risk and made management decisions using a conceptual prototype of AI-based CDS, automated CDS, or no decision support. The conceptual prototype represented contemporary risk calculators based on traditional machine learning models (eg, random forest, neural networks, logistic regression) that incorporate additional predictors alongside traditional risk factors. Primary outcomes were correct risk assessment and patient management (prescription of aspirin, statins, and antihypertensives; referral for advanced examinations). Decision-making time and perceptions about AI utility were also measured. Results: In total, 102 doctors from all 7 geographical regions of Indonesia participated. Most (n=85, 83%) participants were 26-35 years of age, and 57 (56%) were male, with a median of 6 (IQR 4.75) years of clinical experience. AI-based CDS improved risk assessment by 27% (χ22 (n=102)=48.875, P<.001) when compared to unassisted risk assessment, equating to 1 additional correct risk classification for every 3.7 patients where doctors used AI (number needed to treat=3.7, 95% CI 2.9-5.2). The prescription of statins also improved by 29% (χ22 (n=102)=36.608, P<.001). In pairwise comparisons, doctors who were assisted by the AI-based CDS correctly assessed significantly more cases (z=-5.602, n=102, adjusted P<.001) and prescribed the appropriate statin more often (z=-4.936, adjusted P<.001, medium effect size r=0.35) when compared with the control. AI-assisted cases required less time (estimated marginal means 63.6 s vs 72.8 s, F2, 772.8=5.710, P=.003). However, improvements in the prescription of aspirin and antihypertensives did not reach statistical significance (P=.08 and P=.30, respectively). No improvement was observed in referral decisions. Participants generally viewed AI-based CDS positively, with 81 (79%) agreeing or strongly agreeing that they would follow its recommendations and 82 (82%) indicating they would use it if given access. They believed CDS could enhance the efficiency of risk assessment, particularly in high-volume primary care settings, while noting the need to verify AI recommendations against clinical guidelines for each patient. Conclusions: Improvements in risk assessment and statin prescription, coupled with reduced decision-making time, highlight the potential utility of AI in ASCVD risk assessment, particularly in resource-constrained settings where efficient use of health care resources and doctors' time is crucial. Further research is needed to ascertain whether improvements observed in this online study translate to real-world low-resource settings.

Indexed as

Artificial IntelligenceCardiovascular DiseasesDecision Support Systems, ClinicalGeneral PractitionersAdultFemaleHealth ResourcesHumansIndonesiaMaleMiddle AgedRisk Assessmentartificial intelligenceautomationclinical decision-makingclinical decision supportheart disease risk factorsrisk assessment

Identifiers

PMID41289576
PMCPMC12646556

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.